Krukenberg tumours: which patients should be considered for surgery?-a narrative literature review.

IF 1.5 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2024-10-31 Epub Date: 2024-10-29 DOI:10.21037/tcr-24-904
Sabina Ioana Nistor, Hooman Soleymani Majd
{"title":"Krukenberg tumours: which patients should be considered for surgery?-a narrative literature review.","authors":"Sabina Ioana Nistor, Hooman Soleymani Majd","doi":"10.21037/tcr-24-904","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Krukenberg tumours (KTs) are metastatic signet ring cell (SRC) adenocarcinomas of the ovary, arising from the stomach in most cases (70%). Other common primary sites are the colon, appendix and breast. The use of the term \"Krukenberg tumour\" is inconsistent in the literature which makes data interpretation difficult. Prognosis of KTs is dismal and, in the absence of randomised controlled trials, the best treatment strategies remain controversial. Evidence from retrospective studies suggests that metastectomy is associated with improved survival. Our narrative literature review set out to determine which patients gain maximal survival benefit from surgical management.</p><p><strong>Methods: </strong>A comprehensive literature search was performed using PubMed and Google Scholar databases, from 1 January 2000 to 15 July 2024, with the terms 'Krukenberg', 'metastatic mucinous adenocarcinoma of ovary'. This search identified 20 full-text manuscripts, including data on 1,815 patients.</p><p><strong>Key content and findings: </strong>We found that the overall prognosis of these patients remains poor, with a median overall survival (mOS) ranging between 9 and 50 months. Metastectomy is associated with survival benefit only when all visible disease is removed (R0): mOS in patients with microscopic residual disease (R1) or gross residual disease (R2) is similar to mOS in unresected patients (11 <i>vs.</i> 10 months). The following other factors have been identified as independent prognostic factors for survival in multivariate analyses: heated intraperitoneal chemotherapy (HIPEC), adjuvant chemotherapy, curative surgery for the primary tumour, i.e., gastrectomy, no ascites, non-gastric origin, a good performance status, less extensive metastatic disease, i.e., no extra-ovarian disease or no extra-pelvic disease, no peritoneal carcinomatosis or a low Peritoneal Cancer Index (PCI), smaller size of lesion, no SRC features, expression of oestrogen receptor-β (ER-β) and progesterone receptors (PR), metachronous tumours, linitis plastica, tumour grade.</p><p><strong>Conclusions: </strong>Multiple retrospective analyses have demonstrated that metastectomy is associated with a survival benefit in patients with metastatic mucinous ovarian adenocarcinomas. However, patients with poor prognostic factors are less likely to benefit from surgery and should be counselled accordingly. Diagnostic laparoscopy could be considered before debulking surgery, to assess resectability of disease and to avoid a futile exploratory laparotomy. HIPEC after cytoreductive surgery (CRS) remains controversial, with possible survival benefit for KTs of gastric origin, particularly when peritoneal dissemination is present but the PCI is low.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"13 10","pages":"5664-5677"},"PeriodicalIF":1.5000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543025/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-904","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Krukenberg tumours (KTs) are metastatic signet ring cell (SRC) adenocarcinomas of the ovary, arising from the stomach in most cases (70%). Other common primary sites are the colon, appendix and breast. The use of the term "Krukenberg tumour" is inconsistent in the literature which makes data interpretation difficult. Prognosis of KTs is dismal and, in the absence of randomised controlled trials, the best treatment strategies remain controversial. Evidence from retrospective studies suggests that metastectomy is associated with improved survival. Our narrative literature review set out to determine which patients gain maximal survival benefit from surgical management.

Methods: A comprehensive literature search was performed using PubMed and Google Scholar databases, from 1 January 2000 to 15 July 2024, with the terms 'Krukenberg', 'metastatic mucinous adenocarcinoma of ovary'. This search identified 20 full-text manuscripts, including data on 1,815 patients.

Key content and findings: We found that the overall prognosis of these patients remains poor, with a median overall survival (mOS) ranging between 9 and 50 months. Metastectomy is associated with survival benefit only when all visible disease is removed (R0): mOS in patients with microscopic residual disease (R1) or gross residual disease (R2) is similar to mOS in unresected patients (11 vs. 10 months). The following other factors have been identified as independent prognostic factors for survival in multivariate analyses: heated intraperitoneal chemotherapy (HIPEC), adjuvant chemotherapy, curative surgery for the primary tumour, i.e., gastrectomy, no ascites, non-gastric origin, a good performance status, less extensive metastatic disease, i.e., no extra-ovarian disease or no extra-pelvic disease, no peritoneal carcinomatosis or a low Peritoneal Cancer Index (PCI), smaller size of lesion, no SRC features, expression of oestrogen receptor-β (ER-β) and progesterone receptors (PR), metachronous tumours, linitis plastica, tumour grade.

Conclusions: Multiple retrospective analyses have demonstrated that metastectomy is associated with a survival benefit in patients with metastatic mucinous ovarian adenocarcinomas. However, patients with poor prognostic factors are less likely to benefit from surgery and should be counselled accordingly. Diagnostic laparoscopy could be considered before debulking surgery, to assess resectability of disease and to avoid a futile exploratory laparotomy. HIPEC after cytoreductive surgery (CRS) remains controversial, with possible survival benefit for KTs of gastric origin, particularly when peritoneal dissemination is present but the PCI is low.

克鲁肯贝格肿瘤:哪些患者应考虑手术?
背景和目的:克鲁肯伯格瘤(KTs)是卵巢转移性标志环细胞腺癌(SRC),大多数病例(70%)来自胃部。其他常见的原发部位为结肠、阑尾和乳腺。文献中对 "克鲁肯贝格肿瘤 "一词的使用并不一致,这给数据解释带来了困难。克鲁肯贝格肿瘤的预后很差,由于缺乏随机对照试验,最佳治疗策略仍存在争议。回顾性研究的证据表明,转移瘤切除术与生存率的提高有关。我们的叙述性文献综述旨在确定哪些患者能从手术治疗中获得最大的生存获益:使用 PubMed 和 Google Scholar 数据库,以 "Krukenberg"、"转移性卵巢粘液腺癌 "为关键词,对 2000 年 1 月 1 日至 2024 年 7 月 15 日期间的文献进行了全面检索。此次检索共发现 20 篇全文手稿,包括 1,815 名患者的数据:我们发现这些患者的总体预后仍然很差,中位总生存期(mOS)在9至50个月之间。只有切除所有可见病灶(R0)后,才会对患者的生存有利:有显微镜下残留病灶(R1)或严重残留病灶(R2)的患者的中位总生存期与未切除患者的中位总生存期相似(11 个月对 10 个月)。在多变量分析中,以下其他因素被确定为生存期的独立预后因素:腹腔内加热化疗(HIPEC)、辅助化疗、原发肿瘤的根治性手术,即胃切除术、无腹水、非胃源性、良好的表现状态、较少的广泛转移性疾病,即:无卵巢外疾病或无腹水、无卵巢外疾病或盆腔外疾病、无腹膜癌或腹膜癌指数(PCI)较低、病灶较小、无 SRC 特征、雌激素受体-β(ER-β)和孕激素受体(PR)表达、并发肿瘤、浆膜炎、肿瘤分级:多项回顾性分析表明,对转移性粘液性卵巢腺癌患者实施转移灶切除术可提高其生存率。然而,预后不良的患者从手术中获益的可能性较小,因此应给予相应的指导。在进行剥除手术前,可考虑进行诊断性腹腔镜检查,以评估疾病的可切除性,避免徒劳的探查性开腹手术。细胞减灭术(CRS)后的HIPEC仍存在争议,胃源性KT可能对生存有利,尤其是当腹膜播散但PCI较低时。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信